机构:[1]National Engineering Research Centre of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China.[2]La Trobe Institute of Molecular Science, School of Molecular Science, La Trobe University Bundoora, Victoria 3085, Australia.[3]Department of Gastroenterology, XinQiao Hospital, Third Military Medical University, Chongqing, China.[4]Department of General Surgery and Centre of Minimal Invasive Gastrointestinal Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.[5]Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China
Interleukin (IL)-induced inflammatory responses are critical for the pathogenesis of Helicobacter pylori (H. pylori)-induced gastritis. IL-33 represents a recently discovered proinflammatory cytokine involved in inflammatory diseases, but its relevance to H. pylori-induced gastritis is unknown. Here, we found that gastric IL-33 mRNA and protein expression were elevated in gastric mucosa of both patients and mice infected with H. pylori, which is positively correlated with bacterial load and the degree of gastritis. IL-33 production was promoted via extracellular regulated protein kinases (ERK) signaling pathway activation by gastric epithelial cells in a cagA-dependent manner during H. pylori infection, and resulted in increased inflammation and bacteria burden within the gastric mucosa. Gastric epithelial cell-derived IL-33 promoted TNF-α production from mast cells in vitro, and IL-33 increased TNF-α production in vivo. Increased TNF-α inhibited gastric epithelial cell proliferation, conducing to the progress of H. pylori-associated gastritis and bacteria colonization. This study defined a patent regulatory networks involving H. pylori, gastric epithelial cell, IL-33, mast cell, and TNF-α, which jointly play a pathological effect within the gastric circumstances. It may be a valuable strategy to restrain this IL-33-dependent pathway in the treatment of H. pylori-associated gastritis.
基金:
This work was funded by the National Natural Science Foundation of
China (grant number: 81670510) and National Key Research and Development
Program of China (grant number: 2016YFC1302200).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类|2 区生物
小类|2 区细胞生物学
最新[2023]版:
大类|1 区生物学
小类|2 区细胞生物学
第一作者:
第一作者机构:[1]National Engineering Research Centre of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China.
通讯作者:
推荐引用方式(GB/T 7714):
Yi-pin Lv,Yong-sheng Teng,Fang-yuan Mao,et al.Helicobacter pylori-induced IL-33 modulates mast cell responses, benefits bacterial growth, and contributes to gastritis.[J].Cell death & disease.2018,9(5):457.doi:10.1038/s41419-018-0493-1.
APA:
Yi-pin Lv,Yong-sheng Teng,Fang-yuan Mao,Liu-sheng Peng,Jin-yu Zhang...&Yuan Zhuang.(2018).Helicobacter pylori-induced IL-33 modulates mast cell responses, benefits bacterial growth, and contributes to gastritis..Cell death & disease,9,(5)
MLA:
Yi-pin Lv,et al."Helicobacter pylori-induced IL-33 modulates mast cell responses, benefits bacterial growth, and contributes to gastritis.".Cell death & disease 9..5(2018):457